Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy; Says Expects To End 2022 With $25M-$35M In Cash And Investments
- MARIO-4 registration study in frontline metastatic triple negative breast cancer to be initiated by year end 2022 -
- MARIO-P platform study in multiple solid tumors to be initiated on a rolling basis in 3Q 2022
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI)
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setback For Merck’s HIV Program, Decision Day For Daré
Here's a roundup of top developments in the biotech space over the last 24 hours:
Infinity Pharmaceuticals’s Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, Infinity Pharmaceuticals's (NASDAQ:INFI) reported sales totaled $512.00 thousand. Despite a 2.86% increase in earnings, the company posted a loss of $11.25 million.
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
Quick Take Technical Analysis: Infinity Pharmaceuticals, Inc
Infinity Pharmaceuticals, Inc (NASDAQ: INFI) has been trading in a fairly consistent downtrend since Sept. 2 when the stock reached a high of $3.89.